Percos India Pvt. Ltd. is a leading dermatology-focused pharmaceutical and skincare company. Founded by renowned dermatologist Dr. V.K. Upadhyaya. Based in New Delhi, Percos has built a strong presence in the doctor-prescribed and medical aesthetics market, with a portfolio addressing skin disorders such as psoriasis, acne, wrinkles, hyperpigmentation, and skin aging.

Vedaderm, one of Percos’ flagship brands, includes a range of cosmeceutical and chemical peel products prescribed by dermatologists across India.

Cipla, headquartered in Mumbai, is India’s third-largest pharmaceutical company, with a broad portfolio across therapeutic areas. The company manufactures, markets, and distributes pharmaceutical products globally, with a growing focus on skincare and dermatology.

Percos engaged Novistra Capital to advise on a strategic brand divestment, with the aim of identifying a long-term partner to take Vedaderm to the next stage of growth. Novistra structured and managed a focused process to secure a transaction with Cipla, aligning on strategic value, market positioning, and brand potential.

Drawing on its experience in healthcare and pharmaceutical transactions, Novistra ensured a smooth carve-out and negotiated a brand transfer that preserved legacy while enabling future scale.

Percos sold its Vedaderm brand to Cipla, allowing the company to focus on core areas of innovation and product development within dermatology. For Cipla, the acquisition expands its cosmeceutical and prescription skincare offerings and enhances its footprint in the fast-growing medical aesthetics segment.